An update from Nutriband ( (NTRB) ) is now available.
Nutriband has extended its Chinese patent for the AVERSA™ abuse-deterrent transdermal technology to Macao, marking a significant expansion in its global intellectual property portfolio. This move supports the company’s strategic development of AVERSA™ Fentanyl, which could become the first abuse-deterrent opioid patch, potentially impacting market dynamics in opioid safety and accessibility.
More about Nutriband
Nutriband Inc. is engaged in developing transdermal pharmaceutical products, focusing on abuse-deterrent technologies. Their AVERSA™ technology, which can be incorporated into transdermal patches, aims to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
YTD Price Performance: 65.95%
Average Trading Volume: 24,845
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $42.76M
See more data about NTRB stock on TipRanks’ Stock Analysis page.